Meeting Report: Risk Assessment of Tamiflu Use Under Pandemic Conditions
暂无分享,去创建一个
Jürg Oliver Straub | Mark Crane | Chris Watts | Andrew C. Singer | Elise Cartmell | Nikolaos Voulvoulis | Andrew C. Johnson | Brian Ellor | Tony Rachwal | Tatiana Boucard | Jerker Fick | Stephen Bird | John Churchley | Jayne V. Brian | Miles A. Nunn | J. Oxford | J. Brian | J. Fick | N. Voulvoulis | E. Cartmell | J. Churchley | A. Boxall | A. Johnson | C. Knowles | A. Singer | M. Nunn | M. Crane | S. Toovey | J. Straub | C. Watts | N. Roberts | C. Accinelli | Cesare Accinelli | Maria Ludovica Saccà | A. Caracciolo | Stephen Toovey | Alistair Boxall | M. Saccà | C. Chubb | Chris Chubb | Peter Marsden | Matthew Sanders | A. Terry | Bruce M. Howard | Chris J. Knowles | Simon Jackman | Anna Barra Caracciolo | Ian Bernard | Sandra Costigan | Michael J. Dempsey | Bob Dorrington | John Holmes | Tom Hutchinson | Franz Karcher | Samuel L. Kelleher | Gerald Noone | John Oxford | Noel Roberts | Mike Roberts | Adrian Terry | Dean Thomas | Rodney Townsend | B. Ellor | R. Townsend | Mike Roberts | M. Sanders | B. Howard | T. Boucard | Thomas Hutchinson | M. Dempsey | John Holmes | P. Marsden | F. Karcher | S. Costigan | S. Jackman | Ian Bernard | S. Bird | B. Dorrington | G. Noone | T. Rachwal | Deanna Thomas
[1] D. Smee,et al. Peramivir (BCX-1812, RWJ-270201): potential new therapy for influenza , 2002, Expert opinion on investigational drugs.
[2] R. Webster,et al. Neuraminidase Inhibitor-Resistant Influenza Viruses May Differ Substantially in Fitness and Transmissibility , 2005, Antimicrobial Agents and Chemotherapy.
[3] B. Levin,et al. Antiviral Resistance and the Control of Pandemic Influenza , 2007, PLoS medicine.
[4] Mitchell S. Wilbanks,et al. EUROPEAN CENTRE FOR ECOTOXICOLOGY AND TOXICOLOGY OF CHEMICALS , 2005 .
[5] F. Aoki,et al. Influenza Virus Susceptibility and Resistance to Oseltamivir , 2005, Antiviral therapy.
[6] D. Cummings,et al. Strategies for mitigating an influenza pandemic , 2006, Nature.
[7] A. Sanabria,et al. Randomized controlled trial. , 2005, World journal of surgery.
[8] John J. Treanor,et al. Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza , 2000 .
[9] B. Lina,et al. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice. , 2005, Antiviral research.
[10] A. Amonsin,et al. H5N1 Oseltamivir-resistance detection by real-time PCR using two high sensitivity labeled TaqMan probes , 2006, Journal of Virological Methods.
[11] P. Ward,et al. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. , 2005, The Journal of antimicrobial chemotherapy.
[12] J. McKimm-Breschkin,et al. News about influenza B drug resistance that cannot be ignored. , 2007, JAMA.
[13] P. Ward,et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. , 2003, Archives of internal medicine.
[14] Liang Tong,et al. Bacterial neuraminidase facilitates mucosal infection by participating in biofilm production. , 2006, The Journal of clinical investigation.
[15] F. Hayden,et al. Antivirals for influenza: historical perspectives and lessons learned. , 2006, Antiviral research.
[16] N. Roberts,et al. Treatment of influenza with neuraminidase inhibitors: virological implications. , 2001, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[17] I. Barr,et al. Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. , 2007, Antiviral research.
[18] P. Ward,et al. Oral oseltamivir treatment of influenza in children , 2001, The Pediatric infectious disease journal.
[19] P. Grenni,et al. Degradation of the antiviral drug oseltamivir carboxylate in surface water samples , 2007 .
[20] Andrew C. Singer,et al. Potential Risks Associated with the Proposed Widespread Use of Tamiflu , 2006, Environmental health perspectives.
[21] S. Trottier,et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial , 2000, The Lancet.
[22] Akio Yamada,et al. OECD Guidelines for Testing of Chemicals , 1982 .
[23] A global assessment of chemical effluent dilution capacities from a macro-scale hydrological model , 2006 .
[24] Mats Tysklind,et al. Antiviral Oseltamivir Is not Removed or Degraded in Normal Sewage Water Treatment: Implications for Development of Resistance by Influenza A Virus , 2007, PloS one.
[25] Sandra Mounier-Jack,et al. Progress and shortcomings in European national strategic plans for pandemic influenza. , 2007, Bulletin of the World Health Organization.